Development of >=1 new carious lesion (caries incidence) · Children with sound primary molars, aged 2-4 years (municipal dental clinics or hospital paediatric clinics, Denmark)
It is very uncertain whether autopolymerised sealant changes development of >=1 new carious lesion (caries incidence) compared with light polymerised sealant (very low certainty).
1 finding from 1 review
Progression of non-cavitated enamel caries · Children with sound primary molars, aged 2-4 years (municipal dental clinics or hospital paediatric clinics, Denmark)
The review found no eligible studies for this question.
1 finding from 1 review
Dental caries increment, DMFT/dmft (whole-tooth level) · Children with caries-free primary first molars (with or without caries on other teeth), aged 1-5 years (paediatric clinic/dental school,…
1 finding from 1 review
Progression of non-cavitated enamel caries · Children with caries-free primary first molars (with or without caries on other teeth), aged 1-5 years (paediatric clinic/dental school,…
The review found no eligible studies for this question.
1 finding from 1 review
Progression of non-cavitated enamel caries · Children with caries-free or non-cavitated carious lesion primary molars, aged 3-7 years (paediatric department, dental hospital, France)
The review found no eligible studies for this question.
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
It is very uncertain whether antithrombin changes major bleeding compared with no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found